Trending Molecules and Generic Drug Opportunities: Blockbuster Drugs With Upcoming Patent Expirations (2026–2030)
The pharmaceutical industry is undergoing a major change as patent exclusivity expires for popular drugs, highlighting vast generic drug opportunities. This shift will open up a $236 billion opportunity for generic and biosimilar manufacturers between 2025 and 2030. This significant loss of patent protection means more than just the end of exclusive rights. It will revolutionize the market, making affordable generics accessible to patients who require life-saving treatments, new medications, and essential therapies.
From 2026 to 2030, the pharmaceutical industry is expected to face a significant “patent cliff.” This means that many popular drugs will lose their patent protection during this time. For pharmaceutical companies, this period presents both challenges and opportunities.
When a drug’s patent expires, the original company may see a drop in sales and profits. However, this also creates generic drug opportunities for manufacturers to enter the market, increase competition, and provide more affordable options to healthcare providers and patients. Additionally, the need to replace these lost sales pushes pharmaceutical companies to innovate, as they develop new drugs to stay competitive.
This article walks you through the patent cliff phenomenon, highlights blockbuster drugs losing exclusivity through 2030, identifies strategic opportunities across therapeutic areas and geographic markets, and reveals how innovators are defending their competitive positions.
What is the patent cliff? How will generics gain an advantage during this time?
The term “patent cliff” refers to a key event in the pharmaceutical industry when many patents for branded drugs expire within a few years. When these patents expire, generic drug manufacturers can enter the market and create cheaper versions of the patented drugs.
How do generics enter the market and capitalize on generic drug opportunities?
Once a brand-name drug’s patent expires, generic manufacturers can produce and sell their versions without any legal issues. They usually prepare in advance, so they are ready to launch as soon as the patent protection ends, seizing immediate generic drug opportunities.
Let’s further discuss the advantages that generics gain during a patent expiry:
- Cost structure advantages: Generic companies have much lower costs than brand-name companies because they don’t have to spend the same amount on drug discovery and development. Instead of going through extensive trials, they can demonstrate that their drugs are equivalent to the branded versions, reducing costs significantly.
- Competitive pricing advantages: Generics often sell their drugs for 30-50% less than the brand-name drugs, making them attractive to patients and insurance companies. As more generics enter the market, competition drives prices even lower, and sometimes by as much as 80-90%.
- Volume and scale advantages: Generics benefit from producing large quantities of drugs, lowering their manufacturing costs. This leads to even lower prices, which encourages more sales.
- Global market advantages: The patent cliff especially benefits generic manufacturers in developing countries where high drug prices are unaffordable, allowing them to serve these markets profitably while offering lower prices.
- Healthcare system benefits: The introduction of generic drugs can help healthcare systems save money on rising medicine costs, as the lower prices reduce budget pressures while still providing quality treatment.
- Patient access improvements: Patients gain increased access to affordable medicines through generic alternatives. It removes financial barriers to essential treatments as well as improves medication adherence rates across populations.
These competitive advantages are leading to significant market growth in generics. But how big is this opportunity, and which segments will grow the most? Let’s explore these questions in the next section.
Global generic drug market: Growth projections and generic drug opportunities to 2030
Based on the latest market research, here’s a comprehensive analysis of market size and growth projections:
- The global market for generic drugs is expected to be valued between USD 431.10 billion in 2025 and could reach up to USD 611.17 billion by 2030, growing at rates between 4.23% and 7.23%. The differences in these estimates show that the generics market is diverse. While traditional small-molecule generics face tough price competition, complex generics and biosimilars are growing more quickly, presenting layered generic drug opportunities.
- The oncology sector is the fastest-growing area, with a projected growth rate of 9.21% per year until 2030, driven by the expiration of patents for major cancer drugs. High-value cancer treatments are projected to create about $25 billion in opportunities for oncology and immunology biosimilars by 2029.
- Regionally, while North America held 33.20% of the market in 2024, the Asia-Pacific region is positioned for the fastest growth at 8.19% annually through 2030. This growth is attributed to improved healthcare access, favorable regulations, and manufacturing hubs in countries like India and China.
- Biosimilars, too, are expected to surpass USD 40 billion globally by 2030, becoming an important growth driver in the industry as manufacturers are shifting their focus to these higher-margin products.
These market projections become clearer when we examine the specific blockbuster drugs losing patent protection.
Let’s explore which molecules are transitioning from exclusive markets to competitive ones.
Key drugs facing patent expiry (2025-2030)
The following table synthesizes data from multiple industry reports to provide a comprehensive list of high-value drugs anticipated to lose patent protection between 2025 and 2030. It is important to note that expiration dates can vary by region and may be subject to change due to litigation, settlements, or patent term extensions.
| Drug Name (Generic Name) | Company | Therapeutic Area | Projected Patent Expiration |
| Ozempic (semaglutide) | Novo Nordisk | Diabetes | 2025 (March) – 2026 |
| Keytruda (pembrolizumab) | Merck | Oncology | 2025 (July) – 2028 |
| Eliquis (apixaban) | Bristol Myers Squibb/Pfizer | Cardiovascular | 2025 (February) – 2029 |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Hematology/Oncology | 2025 (April) |
| Januvia (sitagliptin) | Merck | Diabetes | 2025 (January) |
| Opdivo (nivolumab) | Bristol Myers Squibb | Oncology | 2025 (October) – 2028 |
| Trulicity (dulaglutide) | Eli Lilly | Diabetes | 2025 (June) – 2027 |
| Ibrance (palbociclib) | Pfizer | Oncology | 2025 (August) – 2027 |
| Enbrel (etanercept) | Amgen | Rheumatology | 2025 (September) |
| Xarelto (rivaroxaban) | Johnson & Johnson/Bayer | Cardiovascular | 2025 (May) – 2026 |
| Eylea (aflibercept) | Regeneron/Bayer | Ophthalmology | 2025 (November) – 2026 |
| Stelara (ustekinumab) | Johnson & Johnson | Immunology | 2025 (December) |
| Jardiance (empagliflozin) | Boehringer Ingelheim/Eli Lilly | Diabetes/Heart Failure | 2025 (February) |
| Dupixent (dupilumab) | Regeneron/Sanofi | Immunology | 2025 (November) – 2027 |
| Ocrevus (ocrelizumab) | Roche | Multiple Sclerosis | 2025 (December) – 2029 |
| Cosentyx (secukinumab) | Novartis | Immunology | 2025 (April) – 2030 |
| Prolia/Xgeva (denosumab) | Amgen | Osteoporosis/Oncology | 2025 – 2026 |
| Yervoy (ipilimumab) | Bristol Myers Squibb | Oncology | 2025 |
| Perjeta (pertuzumab) | Roche | Oncology | 2025 – 2026 |
| Darzalex (daratumumab) | Genmab/Johnson & Johnson | Oncology | 2026 |
| Soliris (eculizumab) | AstraZeneca | Hematology/Neurology | 2027 |
| Repatha (evolocumab) | Amgen | Cardiovascular | 2028 – 2030 |
| Entresto (sacubitril/valsartán) | Novartis | Heart Failure | 2025 (July) |
Investors, manufacturers, and healthcare systems should pay attention to new generic drug opportunities in the market
For example, high-value drugs such as Entresto (sacubitril/valsartan) and Xarelto (rivaroxaban) represent strong opportunities for generic development. To accelerate development timelines, explore Credevo’s catalogue of ten ready-to-use bioequivalence study protocols, each designed in alignment with the FDA and EMA regulatory guidelines: https://credevo.com/s/bioequivalence-study-protocol-catalogue/. These standardized protocols can significantly streamline study planning and simplify generic submissions.
Moving forward, it is also important to know where to focus efforts to maximize these opportunities, as discussed in the following sections.
Four therapeutic areas driving generic drug opportunities and growth
The best opportunities in the drug market are in complex therapeutic areas where popular drugs are losing their patent protection:
1. Oncology: This is the fastest-growing area in the generics market, with an expected annual growth rate of 9.21% until 2030. Major immuno-oncology drugs like Keytruda and Opdivo will lose patent protection in 2028, creating a huge opportunity for biosimilar developers.
2. Diabetes and Obesity: The market for GLP-1 receptor agonists is very active. Patents for drugs like Ozempic and Trulicity are running out, allowing generic and biosimilar manufacturers to enter a market with high global demand.
3. Immunology and Monoclonal Antibodies (mAbs): The global market for mAbs is expected to reach $804 billion by 2033. With patents expiring for popular drugs like Enbrel, Stelara, and Cosentyx, there is a potential $25 billion opportunity for biosimilar manufacturers by 2029.
4. Cardiovascular: There are good opportunities in the anticoagulant market as key drugs like Eliquis and Xarelto will lose patent protection between 2025 and 2026.
While these therapeutic areas highlight where generic drug opportunities are most promising, understanding regional variations is crucial for stakeholders looking to invest or expand in this evolving landscape.
Regional market dynamics: From India to North America
Investment is shifting towards areas with strong manufacturing and growing patient access, revealing diverse generic drug opportunities:
Asia-Pacific (APAC): This region is likely to grow the fastest, with an 8.19% annual growth rate until 2030.
India: As the largest supplier of generic medicines (providing 20% of the global supply), India is a key hub for companies focusing on off-patent opportunities. Its domestic generic market is projected to reach $35.40 billion by 2030.
China: Growth is supported by relaxed regulations and its role as a major manufacturing center. Western pharmaceutical companies are investing heavily in Chinese biotech innovations.
North America: This region currently accounts for 33.20% of global generic sales and is facing a major patent expiration period, with over $200 billion in annual sales at risk by 2030. Companies are increasingly focusing on “product hopping,” which involves creating new delivery methods like subcutaneous injections to extend a drug’s patent life.
Now, let us understand the generic manufacturers’ role in leveraging bioequivalence to secure their market position.
The generic advantage: strategic bioequivalence as competitive defense
Developing solid scientific evidence is essential for generic manufacturers to compete with name-brand medications. Generic manufacturers must view bioequivalence regulations from the FDA, EMA, and other regulatory bodies as a strategic advantage, and not merely a compliance requirement. Strong quality standards, dependable testing procedures, and well-designed studies with sound statistical analyses contribute to the development of a competitive advantage that can endure legal and regulatory obstacles.
Strong bioequivalence evidence is essential for gaining market share and succeeding in an industry where being the first to file can result in substantial financial rewards.
Do you think a ready-to-use bioequivalence protocol would help you accelerate your generic drug development, saving you months of development time and regulatory preparation? Credevo has developed a catalogue of 10 bioequivalence study protocols, scientifically validated and aligned with the FDA and EMA guidelines, covering key molecules in areas like cardiology, oncology, and immunology. These protocols provide detailed study designs and pharmacokinetic assessments to support efficient generic development.
Conclusion
For generic and biosimilar manufacturers, the upcoming patent cliff from 2026 to 2030 offers a revolutionary $236 billion opportunity that will change access to vital treatments globally. Generics will reduce costs and improve patient adherence by taking advantage of expirations in high-value fields like cancer, diabetes, immunology, and cardiovascular treatments. While emerging markets in the Asia-Pacific, led by China and India, become hotspots for growth and investment in generic drug opportunities, innovators must adjust with strong defense strategies. In the end, this period of transition promises a fairer healthcare environment, encouraging competition and innovation for the benefit of people everywhere.
Are you planning a bioequivalence study for your generic formulation? Or facing challenges with one that’s already in progress?
If you are planning or need support throughout the study execution process, our team will support you at all stages of the process. You can communicate with us to discuss your specific needs, from design to implementation.
You can also explore our ready-to-use bioequivalence protocols here:
Please fill in the details below to connect with us with your requests.